AMBS This company is growing more and more as we s

AMBS This company is growing more and more as we speak! Amarantus recently completed the acquisition of Cutanogen Corporation (Cutanogen) from Lonza Walkersville, Inc., a subsidiary of Lonza Group Ltd. Cutanogen has an exclusive worldwide license to intellectual property rights associated with Engineered Skin Substitute (ESS). ESS is a full thickness skin replacement product prepared from autologous (patient's own) tissue-engineered skin cells in development for the treatment of severe burns. ESS received orphan drug designation from the FDA for the treatment of hospitalized patients with deep partial and full thickness burns requiring grafting. Amarantus expects to commence a Phase 2 study of ESS in the U.S. in the third quarter of 2015. Amarantus is also developing MANF (mesencephalic-astrocyte-derived neurotrophic factor), which was discovered by the company’s own discovery platform, PhenoGuard. MANF is being developed for the treatment of brain and ophthalmic disorders and has received Orphan Drug Designation from the FDA and the European Medicines Agency (EMA) for the treatment of Retinitis Pigmentosa.